CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

This trial is testing a type of CAR T-cell therapy — where immune cells are engineered to target cancer — for children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that has relapsed or failed to respond to standard chemotherapy. **You may be eligible if...** - You have relapsed, refractory, or high-risk T-cell leukemia - Your disease failed to respond to or relapsed after standard chemotherapy - Your heart and lung function are adequate - Your performance score (Karnofsky/Lansky) is at least 50 - Adequate kidney, liver, and bone marrow function **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active hepatitis B or C, or HIV - You have a genetic bone marrow failure syndrome (except Down syndrome) - You had a severe reaction to prior CAR T-cell therapy - You have grade 2–4 active graft-versus-host disease from a prior transplant Talk to your doctor to see if this trial is right for you.